10天地西他滨对比3+7化疗序贯异基因移植治疗老年急性髓系白血病:一项开放标签、随机对照3期试验
这项开放标签随机对照3期试验在9个欧洲国家54家医院纳入606例60岁及以上、适合强化化疗的新诊断急性髓系白血病患者,1:1随机接受10天地西他滨或3+7化疗,强烈鼓励异基因造血干细胞移植。中位随访4.0年,4年总生存率两地西他滨组26%对3+7组30%,HR 1.04,p=0.68,无显著差异;地西他滨组3-5级感染、口腔黏膜炎和腹泻发生率更低。
要点
- 10天地西他滨未改善总生存,4年OS 26%对30%(HR 1.04,p=0.68)。
- 两组方案内异基因移植率相似:地西他滨40%对3+7组39%。
- 地西他滨3-5级感染、口腔黏膜炎和腹泻发生率低于3+7组。
核心结论
- 在适合强化化疗的老年急性髓系白血病患者中,10天地西他滨未改善总生存,但安全性优于3+7化疗。
- 作者认为,对于无有利遗传学的适合老年急性髓系白血病患者,地西他滨可考虑作为耐受性更好且疗效足够的3+7诱导替代方案。
研究设计与样本
- 开放标签、随机对照、3期试验,在9个欧洲国家的54家医院开展。
- 纳入606例60岁及以上、新诊断且未治疗、ECOG体能状态评分2分及以下、适合强化化疗的急性髓系白血病患者,1:1随机分配至地西他滨组(n=303)或3+7组(n=303)。
- 地西他滨组首个28天周期第1-10天给予地西他滨20 mg/m2,后续28天周期给予5天或10天地西他滨;3+7组前3天给予柔红霉素60 mg/m2、前7天给予阿糖胞苷200 mg/m2,后续1-3个额外化疗周期;强烈鼓励异基因造血干细胞移植。
- 主要终点为意向治疗人群的总生存;安全性在所有接受分配治疗的患者中评估。
- 研究于2014年12月1日至2019年8月20日随机入组,期中分析显示无效后,数据与安全监查委员会于2019年5月22日建议考虑患者风险获益后研究按计划继续;最终分析数据截止日期为2021年6月30日。
主要发现
- 中位随访4.0年(IQR 2.9-4.8),4年总生存率地西他滨组26%(95% CI 21-32)对3+7组30%(95% CI 24-35),死亡风险比HR 1.04(95% CI 0.86-1.26),p=0.68。
- 方案内异基因造血干细胞移植率两组相似:地西他滨组122/303例(40%)对3+7组118/303例(39%)。
- 3-5级不良事件发生率地西他滨组254/302例(84%)对3+7组279/298例(94%)。
- 3-5级感染发生率地西他滨组41%(125/302)对3+7组53%(158/298),口腔黏膜炎地西他滨组2%(7/302)对3+7组10%(31/298),腹泻地西他滨组1%(3/302)对3+7组8%(24/298),地西他滨组均低于3+7组。
- 治疗相关死亡率地西他滨组12%(35/302)对3+7组14%(41/298)。
关键数值与推荐
- 地西他滨给药方案:20 mg/m2,首个28天周期第1-10天,后续28天周期5天或10天。
- 3+7方案:柔红霉素60 mg/m2前3天,阿糖胞苷200 mg/m2前7天,后续1-3个额外化疗周期。
- 主要终点4年总生存率:地西他滨组26%(95% CI 21-32)对3+7组30%(95% CI 24-35),HR 1.04(95% CI 0.86-1.26),p=0.68。
临床怎么用
- 作者认为,对于无有利遗传学的适合老年急性髓系白血病患者,地西他滨可考虑作为耐受性更好且疗效足够的3+7诱导替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy with decitabine monotherapy could improve outcomes. METHODS: This open-label, randomised, controlled, phase 3 trial was conducted at 54 hospitals in nine European countries. Patients aged 60 years and older who were newly diagnosed with acute myeloid leukaemia and had not yet been treated were enrolled if they had an Eastern Cooperative Oncology Group performance status of 2 or less and were eligible for intensive chemotherapy. Patients were randomly assigned (1:1) to receive decitabine or standard chemotherapy (known as 3 + 7). For the decitabine group, decitabine (20 mg/m2) was administered for the first 10 days in the first 28-day cycle, followed by 28-day cycles consisting of 5 days or 10 days of decitabine. For the 3 + 7 group, daunorubicin (60 mg/m2) was administered over the first 3 days and cytarabine (200 mg/m2) over the first 7 days, followed by 1-3 additional chemotherapy cycles. Allogeneic HSCT was strongly encouraged. Overall survival in the intention-to-treat population was the primary endpoint. Safety was assessed in all patients who received the allocated treatment. This trial is registered at ClinicalTrials.gov, NCT02172872, and is closed to new participants. FINDINGS: Between Dec 1, 2014, and Aug 20, 2019, 606 patients were randomly assigned to the decitabine (n=303) or 3 + 7 (n=303) group. Following an interim analysis which showed futility, the IDMC recommended on May 22, 2019, that the study continued as planned considering the risks and benefits for the patients participating in the study. The cutoff date for the final analysis presented here was June 30, 2021. At a median follow-up of 4·0 years (IQR 2·9-4·8), 4-year overall survival was 26% (95% CI 21-32) in the decitabine group versus 30% (24-35) in the 3 + 7 group (hazard ratio for death 1·04 [95% CI 0·86-1·26]; p=0·68). Rates of on-protocol allogeneic HSCT were similar between groups (122 [40%] of 303 patients for decitabine and 118 [39%] of 303 patients for 3+7). Rates of grade 3-5 adverse events were 254 (84%) of 302 patients in the decitabine group and 279 (94%) of 298 patients in the 3 + 7 group. The rates of grade 3-5 infections (41% [125 of 302] vs 53% [158 of 298]), oral mucositis (2% [seven of 302] vs 10% [31 of 298]) and diarrhoea (1% [three of 302] vs 8% [24 of 298]) were lower in the decitabine group than in the 3 + 7 group. Treatment-related deaths were reported for 12% (35 of 302) of patients in the decitabine group and 14% (41 of 298) in the 3 + 7 group. INTERPRETATION: 10-day decitabine did not improve overall survival but showed a better safety profile compared with 3 + 7 chemotherapy in older patients with acute myeloid leukaemia eligible for intensive chemotherapy. Decitabine could be considered a better-tolerated and sufficiently efficacious alternative to 3 + 7 induction in fit older patients with acute myeloid leukaemia without favourable genetics. FUNDING: Janssen Pharmaceuticals.
引用
- Lübbert M, Wijermans PW, Kicinski M, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2023. PMID: 37914482. doi:10.1016/S2352-3026(23)00273-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。